An ongoing theme involving the expansion of facilities and production capacity at multiple sites, including U.S. production buildings and large-scale manufacturing plants and U.K. development sites, to expand the biopharmaceutical CDMO business. This also includes expansion of contract manufacturing under long-term manufacturing agreements.